BIOMAT Database Logo BIOMAT Database Logo

Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. 2012

Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Graduate School of Biomedical Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553 Japan. sanoh@hiroshima-u.ac.jp

Accurate prediction of pharmacokinetics (PK) parameters in humans from animal data is difficult for various reasons, including species differences. However, chimeric mice with humanized liver (PXB mice; urokinase-type plasminogen activator/severe combined immunodeficiency mice repopulated with approximately 80% human hepatocytes) have been developed. The expression levels and metabolic activities of cytochrome P450 (P450) and non-P450 enzymes in the livers of PXB mice are similar to those in humans. In this study, we examined the predictability for human PK parameters from data obtained in PXB mice. Elimination of selected drugs involves multiple metabolic pathways mediated not only by P450 but also by non-P450 enzymes, such as UDP-glucuronosyltransferase, sulfotransferase, and aldehyde oxidase in liver. Direct comparison between in vitro intrinsic clearance (CL(int,in vitro)) in PXB mice hepatocytes and in vivo intrinsic clearance (CL(int,in vivo)) in humans, calculated based on a well stirred model, showed a moderate correlation (r² = 0.475, p = 0.009). However, when CL(int,in vivo) values in humans and PXB mice were compared similarly, there was a good correlation (r² = 0.754, p = 1.174 × 10⁻⁴). Elimination half-life (t(1/2)) after intravenous administration also showed a good correlation (r² = 0.886, p = 1.506 × 10⁻⁴) between humans and PXB mice. The rank order of CL and t(1/2) in human could be predicted at least, although it may not be possible to predict absolute values due to rather large prediction errors. Our results indicate that in vitro and in vivo experiments with PXB mice should be useful at least for semiquantitative prediction of the PK characteristics of candidate drugs in humans.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002678 Chimera An individual that contains cell populations derived from different zygotes. Hybrids,Chimeras,Hybrid
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females

Related Publications

Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver.
December 2019, Xenobiotica; the fate of foreign compounds in biological systems,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.
February 2007, Journal of pharmaceutical sciences,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver.
July 2020, Xenobiotica; the fate of foreign compounds in biological systems,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Prediction of Human Disproportionate and Biliary Excreted Metabolites Using Chimeric Mice with Humanized Liver.
October 2020, Drug metabolism and disposition: the biological fate of chemicals,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver.
January 2009, Drug metabolism and pharmacokinetics,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver.
January 2014, Xenobiotica; the fate of foreign compounds in biological systems,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers.
January 2022, Clinical and translational science,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
[Chimeric mice with humanized liver: mechanism of hepatic hyperplasia induction].
August 2012, Seikagaku. The Journal of Japanese Biochemical Society,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Chimeric mice with humanized liver.
April 2008, Toxicology,
Seigo Sanoh, and Aya Horiguchi, and Kazumi Sugihara, and Yaichiro Kotake, and Yoshitaka Tayama, and Hiroki Ohshita, and Chise Tateno, and Toru Horie, and Shigeyuki Kitamura, and Shigeru Ohta
Quantitative Prediction of OATP-Mediated Disposition and Biliary Clearance Using Human Liver Chimeric Mice.
November 2023, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!